Righting Wright Medical

In the early 90's, already strong in total knee replacements, Wright Medical ambitiously staked out markets in hips, trauma, spine and arthroscopy. Much of the expansion was accomplished through a series of acquisitions, perhaps the most important of which was the 1994 acquisition of Orthomet Inc. But those ambitions were never realized, and Wright spent from 1996 to 1998 changing management several times, laying off large numbers of employees and exiting nearly all of the businesses it tried to get into in 1993-'94, all while sales were flat or in decline. Nevertheless, Warburg Pincus, which bought Wright this month, clearly sees opportunity where others don't.

In the early 1990s, Wright Medical seemed poised to make a serious run at creating the next major US orthopedics company. Fresh from the debacle of the breast implant litigation, the company, then known as Dow Corning Wright, refashioned itself as Wright Medical Technology Inc. , and under new CEO Herb Korthoff, formerly of United States Surgical Corp.(now a unit of Tyco International Ltd. ), began an aggressive move into a wide variety of orthopedic segments [See Deal].

Always strong in total knee replacements, Wright Medical ambitiously staked out markets in hips, trauma, spine, and arthroscopy, and even...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business Strategy

When VC Steps Back: Finding Alternative Biotech Funding

 
• By 

The biotech funding landscape is undergoing a fundamental shift. With traditional VC becoming increasingly cautious and selective, industry executives are exploring new avenues for capital. Conversely, this evolution may ultimately benefit the sector's long-term sustainability.

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

 

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By 

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.

Rising Leaders 2025: Abbas Kazimi’s Vision For Nimbus Therapeutics

 
• By 

Rising Leader Abbas Kazimi's leadership at Nimbus Therapeutics combines immigrant resilience, patient-first partnerships, contrarian strategic bets and a deeply personal mission driving breakthrough drug discovery innovation.

More from In Vivo

When VC Steps Back: Finding Alternative Biotech Funding

 
• By 

The biotech funding landscape is undergoing a fundamental shift. With traditional VC becoming increasingly cautious and selective, industry executives are exploring new avenues for capital. Conversely, this evolution may ultimately benefit the sector's long-term sustainability.

Podcast: Inside MoonLake’s Fast-Track Vision And $500m Deal

 
• By 

MoonLake Immunotherapeutics is racing ahead in the biotech space with its innovative nanobody SLK and a transformative $500m non-dilutive financing deal. In this episode, its CEO and CFO discuss the company’s rapid clinical progress, financial strategy and ambitions to reshape inflammatory disease.

When Simple Is Best: A Pre-Term Birth Device To End The ‘Silent Emergency’

 
• By 

The Lioness non-surgical silicon ring implant is designed to put an end to pre-term births, sparing maternal anguish and saving health system costs. PregnanTech won the Biomed Israel 2025 medtech start-up award, and Limor Sandach told In Vivo how a non-digital technology beat off stiff competition.